시장보고서

상품코드

1530035

파마 4.0 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 기술별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Pharma 4.0 Market Size, Share & Trends Analysis Report By Type (Software, Services), By Technology (AI/ML, Big Data Analytics, IoT, Blockchain Technology), By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030

발행일: 2024년 07월 | 리서치사:

Grand View Research | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

파마 4.0 시장 성장과 동향:

Grand View Research, Inc.의 최신 보고서에 따르면 세계 파마 4.0 시장 규모는 2024년부터 2030년까지 18.96%의 CAGR을 기록하여 2030년까지 357억 9,000만 달러에 달할 것으로 예상됩니다.

파마 4.0 시장은 개인화된 의료에 대한 수요 증가, 효율성 개선 및 비용 절감의 필요성, 공급망 최적화, 환자 중심 접근 방식에 대한 관심 증가 등 몇 가지 주요 요인에 의해 주도되고 있습니다. 만성질환과 희귀질환의 유병률 증가로 인해 맞춤형 의료에 대한 수요가 증가하고 있습니다. 적층 제조(3D 프린팅)와 모듈형 생산 설비와 같은 파마 4.0 기술은 환자 개개인의 요구에 맞는 맞춤형 의약품과 소량 생산이 가능해지면서 이러한 추세를 더욱 촉진하고 있습니다.

또한, 디지털 기술의 채택이 증가하고 있는 것도 시장 성장을 촉진하고 있습니다. 이러한 기술은 의약품 개발, 제조, 유통 및 환자 치료를 최적화, 개선 및 혁신합니다. 블록체인 기술은 투명성, 추적성, 최적화를 제공하고, 재고 소진을 줄이고, 위조를 방지하고, 전반적인 효율성과 환자 안전을 향상시킴으로써 공급망 관리를 크게 재구성하고 있습니다.

또한, 제약사들이 파마 4.0 기술 도입을 위한 투자를 늘리고 있는 것도 시장 성장의 원동력이 되고 있습니다. 예를 들어, 아스트라제네카(AstraZeneca)는 희귀 신경퇴행성 및 신경근육질환 표적 발굴을 위해 최대 8억 4천만 달러 규모의 계약을 체결한 바 있습니다. 이 계약의 일환으로 아스트라제네카의 알렉시온 사업부는 Verge Genomics와 협력하여 이들 질환에 대한 신약 타겟을 발굴할 예정이며, 4년간의 다중 타겟 계약 기간 동안 양사는 기계 학습을 통해 세포나 동물 모델이 아닌 인간 조직에서 얻은 Verge의 유전체 데이터 세트를 분석할 예정입니다.

파마 4.0 시장 보고서 하이라이트

제품 유형별로 보면 2023년 소프트웨어 분야는 효율성 향상, 컴플라이언스 준수, 생산성 향상 등 다양한 이점으로 인해 소프트웨어 채택이 증가함에 따라 소프트웨어 분야가 시장을 주도했습니다. 또한, IoT 지원 소프트웨어는 제조 공정을 실시간으로 모니터링하고 추적하여 공정 제어를 개선하고 다운타임을 줄이는 데 도움이 됩니다.
기술별로는 AI 도입 확대와 투자 증가로 AI & ML 분야가 가장 큰 시장 점유율을 차지하고 있습니다. 예를 들어, 한 조사에 따르면 제약사 경영진의 75% 이상이 2025년까지 신약 개발 속도를 높이기 위해 AI를 적용할 계획인 것으로 나타났습니다.
용도별로는 신약개발 스타트업의 AI 투자가 증가함에 따라 2023년 신약개발 및 시장개척이 시장을 주도했습니다.
제약 및 생명공학 분야는 2023년 49.8%의 가장 큰 시장 점유율을 차지했습니다. 제약회사들은 제조 공정의 효율성, 생산성 및 품질을 향상시키기 위해 파마 4.0 기술을 점점 더 많이 채택하고 있으며, 이는 이 부문의 성장을 주도하고 있습니다.
북미는 2023년 41.12%의 매출 점유율을 차지하며 세계 시장을 장악했습니다. 이러한 성장은 정부 주도의 증가, 헬스케어 산업의 기술 발전, 주요 시장 기업의 강력한 존재감에 기인합니다.

주요 시장 진출 기업의 최근 동향과 영향 분석
기업/경쟁 분류
주요 기업의 시장 점유율 분석, 2023년
기업 개요
- Microsoft Corporation
- IBM
- Amazon Web Service(AWS)
- SAP
- Oracle
- GE Healthcare
- Siemens Healthineers
- Cisco
- Cinntra
- Dassault Systems
- Nexocode

ksm 24.08.29

Pharma 4.0 Market Growth & Trends:

The global pharma 4.0 market size is expected to reach USD 35.79 billion by 2030, registering a CAGR of 18.96% from 2024 to 2030, according to a new report by Grand View Research, Inc. The pharma 4.0 market is being driven by several key factors, including the rising demand for personalized medicine, the need for improved efficiency and cost reduction, supply chain optimization, and an increasing focus on patient-centric approaches. The growing prevalence of chronic disorders and rare diseases has heightened the demand for personalized medicine. Pharma 4.0 technologies, such as additive manufacturing (3D printing) and modular production facilities, enable the production of personalized medicines and small batches tailored to individual patient needs, supporting this trend.

In addition, increasing adoption of digital technologies is driving the market growth. These technologies optimize, improve, and revolutionize drug development, manufacturing, distribution, and patient care. Blockchain technology has significantly reshaped supply chain management by offering transparency, traceability, and optimization, reducing stockouts, preventing counterfeiting, and enhancing overall efficiency and patient safety.

Furthermore, the market growth is being driven by increasing investments from pharmaceutical companies in adopting Pharma 4.0 technologies. For example, AstraZeneca signed a deal worth up to USD 840 million for the target identification of rare neurodegenerative and neuromuscular diseases. As part of this deal, AstraZeneca's Alexion division will collaborate with Verge Genomics to identify drug targets for these conditions. Over the course of the four-year, multi-target agreement, the companies will utilize machine learning to analyze Verge's genomic datasets, which are derived from human tissue rather than cell or animal models.

Pharma 4. 0 Market Report Highlights:

On the basis of type, the software segment dominated the market in 2023, owing to the increasing adoption of software due to various benefits such as efficiency enhancement, improved compliance and productivity. In addition, the IoT enabled software help in real time monitoring and tracking of manufacturing process, leading to better process control and reduces the downtime
On the basis of technology, the AI & ML segment held the largest market share owing to growing adoption of AI and increasing investments. For instance, as per a survey, over 75% of pharma executives plan to apply AI to speed drug discovery by 2025
On the basis of application, the drug discovery & development dominated the market in 2023 due to increased investment in AI for drug discovery startups
Pharma & biotech segment held the largest market share of 49.8% in 2023. Pharmaceutical companies are increasingly adopting Pharma 4.0 technologies to enhance efficiency, productivity, and quality in their manufacturing processes thereby driving the segment growth
North America dominated the global market with a revenue share of 41.12% in 2023. The growth is attributed to the increasing government initiative, technological advancement in the healthcare industry, and a strong presence of key market players

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
- 1.1.1. Type
- 1.1.2. Technology
- 1.1.3. Application
- 1.1.4. End Use
- 1.1.5. Regional scope
- 1.1.6. Estimates and forecast timeline.
1.2. Research Methodology
1.3. Information Procurement
- 1.3.1. Purchased database.
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
1.4. Information or Data Analysis
- 1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
- 1.6.1. Commodity flow analysis (Model 1)
- 1.6.2. Approach 1: Commodity flow approach
- 1.6.3. Volume price analysis (Model 2)
- 1.6.4. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Pharma 4.0 Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
3.3. Pharma 4.0 Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Technological landscape
  - 3.3.2.3. Economic landscape
- 3.3.3. COVID-19 Impact

Chapter 4. Pharma 4.0 Market: Type Estimates & Trend Analysis

4.1. Type Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Pharma 4.0 Market by Type Outlook
4.4. Software
- 4.4.1. Market estimates and forecast 2018 to 2030 (USD Billion)
4.5. Services
- 4.5.1. Market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 5. Pharma 4.0 Market: Technology Estimates & Trend Analysis

5.1. Technology Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Pharma 4.0 Market by Technology Outlook
5.4. AI & ML
- 5.4.1. Market estimates and forecast 2018 to 2030 (USD Billion)
5.5. Big Data Analytics
- 5.5.1. Market estimates and forecast 2018 to 2030 (USD Billion)
5.6. IoT
- 5.6.1. Market estimates and forecast 2018 to 2030 (USD Billion)
5.7. Block chain Technology
- 5.7.1. Market estimates and forecast 2018 to 2030 (USD Billion)
5.8. Others (Digital twin, Advanced robotics, AR &VR)
- 5.8.1. Market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 6. Pharma 4.0 Market: Application Estimates & Trend Analysis

6.1. Application Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Pharma 4.0 Market by Application Outlook
6.4. Drug Discovery & Development
- 6.4.1. Market estimates and forecast 2018 to 2030 (USD Billion)
6.5. Manufacturing
- 6.5.1. Market estimates and forecast 2018 to 2030 (USD Billion)
6.6. Supply Chain Management
- 6.6.1. Market estimates and forecast 2018 to 2030 (USD Billion)
6.7. Others (Product Lifecycle Management, Personalized Medicine, Regulatory Compliance)
- 6.7.1. Market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 7. Pharma 4.0 Market: End Use Estimates & Trend Analysis

7.1. End Use Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. Global Pharma 4.0 Market by End Use Outlook
7.4. Pharma & Biotech companies
- 7.4.1. Market estimates and forecast 2018 to 2030 (USD Billion)
7.5. Healthcare Providers
- 7.5.1. Market estimates and forecast 2018 to 2030 (USD Billion)
7.6. CRO & CDMO
- 7.6.1. Market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 8. Pharma 4.0 Market: Regional Estimates & Trend Analysis, By type, By technology, By Application, By End Use

8.1. Regional Market Share Analysis, 2023 & 2030
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
8.5. North America
- 8.5.1. U.S.
  - 8.5.1.1. Key country dynamics
  - 8.5.1.2. Regulatory framework/ reimbursement structure
  - 8.5.1.3. Competitive scenario
  - 8.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
- 8.5.2. Canada
  - 8.5.2.1. Key country dynamics
  - 8.5.2.2. Regulatory framework/ reimbursement structure
  - 8.5.2.3. Competitive scenario
  - 8.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
- 8.5.3. Mexico
  - 8.5.3.1. Key country dynamics
  - 8.5.3.2. Regulatory framework/ reimbursement structure
  - 8.5.3.3. Competitive scenario
  - 8.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
8.6. Europe
- 8.6.1. UK
  - 8.6.1.1. Key country dynamics
  - 8.6.1.2. Regulatory framework/ reimbursement structure
  - 8.6.1.3. Competitive scenario
  - 8.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
- 8.6.2. Germany
  - 8.6.2.1. Key country dynamics
  - 8.6.2.2. Regulatory framework/ reimbursement structure
  - 8.6.2.3. Competitive scenario
  - 8.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
- 8.6.3. France
  - 8.6.3.1. Key country dynamics
  - 8.6.3.2. Regulatory framework/ reimbursement structure
  - 8.6.3.3. Competitive scenario
  - 8.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
- 8.6.4. Italy
  - 8.6.4.1. Key country dynamics
  - 8.6.4.2. Regulatory framework/ reimbursement structure
  - 8.6.4.3. Competitive scenario
  - 8.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
- 8.6.5. Spain
  - 8.6.5.1. Key country dynamics
  - 8.6.5.2. Regulatory framework/ reimbursement structure
  - 8.6.5.3. Competitive scenario
  - 8.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
- 8.6.6. Norway
  - 8.6.6.1. Key country dynamics
  - 8.6.6.2. Regulatory framework/ reimbursement structure
  - 8.6.6.3. Competitive scenario
  - 8.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
- 8.6.7. Sweden
  - 8.6.7.1. Key country dynamics
  - 8.6.7.2. Regulatory framework/ reimbursement structure
  - 8.6.7.3. Competitive scenario
  - 8.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
- 8.6.8. Denmark
  - 8.6.8.1. Key country dynamics
  - 8.6.8.2. Regulatory framework/ reimbursement structure
  - 8.6.8.3. Competitive scenario
  - 8.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
8.7. Asia Pacific
- 8.7.1. Japan
  - 8.7.1.1. Key country dynamics
  - 8.7.1.2. Regulatory framework/ reimbursement structure
  - 8.7.1.3. Competitive scenario
  - 8.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
- 8.7.2. China
  - 8.7.2.1. Key country dynamics
  - 8.7.2.2. Regulatory framework/ reimbursement structure
  - 8.7.2.3. Competitive scenario
  - 8.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
- 8.7.3. India
  - 8.7.3.1. Key country dynamics
  - 8.7.3.2. Regulatory framework/ reimbursement structure
  - 8.7.3.3. Competitive scenario
  - 8.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
- 8.7.4. Australia
  - 8.7.4.1. Key country dynamics
  - 8.7.4.2. Regulatory framework/ reimbursement structure
  - 8.7.4.3. Competitive scenario
  - 8.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
- 8.7.5. South Korea
  - 8.7.5.1. Key country dynamics
  - 8.7.5.2. Regulatory framework/ reimbursement structure
  - 8.7.5.3. Competitive scenario
  - 8.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
- 8.7.6. Thailand
  - 8.7.6.1. Key country dynamics
  - 8.7.6.2. Regulatory framework/ reimbursement structure
  - 8.7.6.3. Competitive scenario
  - 8.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
8.8. Latin America
- 8.8.1. Brazil
  - 8.8.1.1. Key country dynamics
  - 8.8.1.2. Regulatory framework/ reimbursement structure
  - 8.8.1.3. Competitive scenario
  - 8.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
- 8.8.2. Argentina
  - 8.8.2.1. Key country dynamics
  - 8.8.2.2. Regulatory framework/ reimbursement structure
  - 8.8.2.3. Competitive scenario
  - 8.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
8.9. MEA
- 8.9.1. South Africa
  - 8.9.1.1. Key country dynamics
  - 8.9.1.2. Regulatory framework/ reimbursement structure
  - 8.9.1.3. Competitive scenario
  - 8.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
- 8.9.2. Saudi Arabia
  - 8.9.2.1. Key country dynamics
  - 8.9.2.2. Regulatory framework/ reimbursement structure
  - 8.9.2.3. Competitive scenario
  - 8.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
- 8.9.3. UAE
  - 8.9.3.1. Key country dynamics
  - 8.9.3.2. Regulatory framework/ reimbursement structure
  - 8.9.3.3. Competitive scenario
  - 8.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
- 8.9.4. Kuwait
  - 8.9.4.1. Key country dynamics
  - 8.9.4.2. Regulatory framework/ reimbursement structure
  - 8.9.4.3. Competitive scenario
  - 8.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 9. Competitive Landscape

9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Key company market share analysis, 2023
9.4. Company Profiles
- 9.4.1. Microsoft Corporation
  - 9.4.1.1. Company overview
  - 9.4.1.2. Financial performance
  - 9.4.1.3. Product benchmarking
  - 9.4.1.4. Strategic initiatives
- 9.4.2. IBM
  - 9.4.2.1. Company overview
  - 9.4.2.2. Financial performance
  - 9.4.2.3. Product benchmarking
  - 9.4.2.4. Strategic initiatives
- 9.4.3. Amazon Web Service (AWS)
  - 9.4.3.1. Company overview
  - 9.4.3.2. Financial performance
  - 9.4.3.3. Product benchmarking
  - 9.4.3.4. Strategic initiatives
- 9.4.4. SAP
  - 9.4.4.1. Company overview
  - 9.4.4.2. Financial performance
  - 9.4.4.3. Product benchmarking
  - 9.4.4.4. Strategic initiatives
- 9.4.5. Oracle
  - 9.4.5.1. Company overview
  - 9.4.5.2. Financial performance
  - 9.4.5.3. Product benchmarking
  - 9.4.5.4. Strategic initiatives
- 9.4.6. GE Healthcare
  - 9.4.6.1. Company overview
  - 9.4.6.2. Financial performance
  - 9.4.6.3. Product benchmarking
  - 9.4.6.4. Strategic initiatives
- 9.4.7. Siemens Healthineers
  - 9.4.7.1. Company overview
  - 9.4.7.2. Financial performance
  - 9.4.7.3. Product benchmarking
  - 9.4.7.4. Strategic initiatives
- 9.4.8. Cisco
  - 9.4.8.1. Company overview
  - 9.4.8.2. Financial performance
  - 9.4.8.3. Product benchmarking
  - 9.4.8.4. Strategic initiatives
- 9.4.9. Cinntra
  - 9.4.9.1. Company overview
  - 9.4.9.2. Financial performance
  - 9.4.9.3. Product benchmarking
  - 9.4.9.4. Strategic initiatives
- 9.4.10. Dassault Systems
  - 9.4.10.1. Company overview
  - 9.4.10.2. Financial performance
  - 9.4.10.3. Product benchmarking
  - 9.4.10.4. Strategic initiatives
- 9.4.11. Nexocode
  - 9.4.11.1. Company overview
  - 9.4.11.2. Financial performance
  - 9.4.11.3. Product benchmarking
  - 9.4.11.4. Strategic initiatives

파마 4.0 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 기술별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Pharma 4.0 Market Size, Share & Trends Analysis Report By Type (Software, Services), By Technology (AI/ML, Big Data Analytics, IoT, Blockchain Technology), By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030

파마 4.0 시장 성장과 동향:

파마 4.0 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 파마 4.0 시장 변수, 동향, 범위

제4장 파마 4.0 시장 : 유형별 추정·동향 분석

제5장 파마 4.0 시장 : 기술별 추정·동향 분석

제6장 파마 4.0 시장 : 용도별 추정·동향 분석

제7장 파마 4.0 시장 : 최종 용도별 추정·동향 분석

제8장 파마 4.0 시장 : 지역별 추정·동향 분석, 유형별, 기술별, 용도별, 최종 용도별

제9장 경쟁 상황